Bloomberg News

Actelion Climbs After Drugmaker Reiterates 2013 Forecast

January 08, 2013

Actelion Ltd. (ATLN) climbed the most in more than five months after the Swiss maker of the Tracleer lung drug reiterated its forecast for 2013.

Actelion rose as much as 3.7 percent to 46.39 Swiss francs, the biggest intraday jump since July 19, and was trading up 3.4 percent at 12:04 p.m. in Zurich. Volume exceeded the three-month daily average by 13 percent.

Earnings in 2013 will about match figures from last year, with “single-digit percentage growth” in 2014 and a double- digit increase in 2015 because of sales of macitentan, a planned successor to Tracleer, the Allschwil-based company said in a presentation posted on its website after the close of trading yesterday.

“Full year 2012 was an exciting year, laying the stepping stone for further success by demonstrating that macitentan is a very good and efficacious drug,” Andrew Weiss, an analyst at Bank Vontobel AB, wrote in a note today. “Earnings guidance for 2013 is confirmed.”

To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus